Hospital Universitario Lucus Agusti

Lugo, Spain

Hospital Universitario Lucus Agusti

Lugo, Spain
SEARCH FILTERS
Time filter
Source Type

Golpe R.,Hospital Universitario Lucus Agusti | Mateos-Colino A.,Hospital Universitario Lucus Agusti | Gonzalez-Juanatey C.,Hospital Universitario Lucus Agusti | Testa-Fernandez A.,Hospital Universitario Lucus Agusti | And 2 more authors.
Lung | Year: 2017

Purpose: It remains unclear whether there is a pathogenic link between chronic obstructive pulmonary disease (COPD) and cardiovascular diseases. Subclinical carotid atherosclerosis is a predictor of future cardiovascular events. Exacerbations increase all-cause mortality in COPD, and exacerbation-like episodes have been described in subjects without COPD. Our objectives were as follows: (1) to confirm the independent association between COPD and carotid atherosclerosis and (2) to asses the possible relationship between COPD exacerbations or exacerbation-like episodes and a higher risk of atherosclerosis. Methods: 127 COPD subjects and 80 control subjects with smoking history were studied. Carotid ultrasound examination was carried out in all subjects. Univariate and multivariate logistic regression analyses were performed in order to assess the relationship between both COPD diagnosis and previous COPD exacerbations (or exacerbation-like episodes in non-COPD subjects) and the presence of carotid atherosclerosis. Results: The prevalence of carotid atherosclerosis was higher in COPD group (65.3 vs. 47.5%, p = 0.01; OR 2.18, 95% CI 1.23–3.88, p < 0.01). Diagnosis of COPD was not independently associated with atherosclerosis, after adjusting for potential confounders. Neither COPD exacerbations nor exacerbation-like episodes in control subjects were associated with a higher risk of atherosclerosis. Conclusion: There is a higher prevalence of carotid atherosclerosis in COPD than in control smokers or ex-smokers, but the differences seem to be related to shared risk factors. We have not found evidence for an increased risk of atherosclerosis associated with COPD exacerbations or exacerbation-like events. Further longitudinal studies should be carried out to confirm these findings. © 2017 Springer Science+Business Media New York


Fernandez Perez A.,Responsable Mezclas Intravenosas y Nutricion Parenteral | Pineiro Conde S.R.,Responsable Atencion Farmaceutica Centros Sociosanitarios | Lopez Rodriguez I.,Responsable Atencion Farmaceutica Pacientes Externos Y Miembro Nucleo Of Seguridad Del Hospital | Perez Rodriguez N.,Farmacia Hospitalaria | Lopez Garcia V.M.,Hospital Universitario Lucus Agusti
Pharmaceutical Care Espana | Year: 2014

Introduction and Objective: To judge the follow-up of the recommendations made by the Ministry of Health. These recommendations are aimed at minimizing the risk of Progressive Multifocal Leukoencephalopathy (PML) occurrence, which is associated with natalizumab treatments provided by the neurologists of our centre. Methods: Check-up of 100% of the patients diagnosed with multiple sclerosis being treated with natalizumab (September 2008-June 2013). Results: During the study period 34 patients received at least one dose of natalizumab. The duration of the treatment was less than one year for 10 patients between 1 and 2 years for 11 patients, and more than 2 years for 13 patients. 24 results of JCV serology were found, 14 of which were positive and 10, negative. No patient had been given immunosuppressant drugs and resonance tests were done on 100% of them. 18 patients were informed at the risk of developing PML, among whom ten had positive JCV serology. Seven of them, had been treated with natalizumab for more than two years. Discussion: Doctors are following the recommendations with the vast majority of patients. Nevertheless, the information that precedes the treatment and once that the second year of it is reached is not generally provided. Due to the fact that there are currently no tools to predict an individual's risk of developing PML, it would be appropriate to carry out a risk stratification based on the presence or absence of certain factors that would allow a safe and effective choice of the most appropriate multiple sclerosis therapy for each patient.


Sehlbach C.,Maastricht University | Thomson C.,Harvard University | Bennett J.,University of Leicester | de Llano L.P.,Hospital Universitario Lucus Agusti | And 6 more authors.
Breathe | Year: 2017

To create an overview on re-certification procedures across the globe, the European Respiratory Society (ERS) organised an educational forum on “Re-certification: current practice and the future” during the 2016 International Congress in London, UK. During this educational forum, the importance of re-certification and international procedures were discussed. Panellists from Japan, the Netherlands, Spain, the UK and the USA presented their respective national re-certification systems. © ERS 2017.


Vazquez-Lopez M.E.,Hospital Universitario Lucus Agusti | Fernandez G.,University of Santiago de Compostela | Diaz P.,University of Santiago de Compostela | Diez-Morrondo C.,Hospital del Bierzo | And 2 more authors.
Atencion Primaria | Year: 2016

Objective: The main aim of this study was to determine the usefulness of an early diagnosis of Lyme disease (LD) in Primary Health Care Centres (PHCC) using the ELISA test as serological screening technique. Methods: A retrospective study (2006-2013) was performed in order to determine the anti-. Borrelia seropositivity in 2,842 people at risk of having LD. The possible relationship between the environment and the area of residence with anti-. Borrelia seropositivity was also studied according to the origin of the specimens (PHCC/Hospital). Results: Overall, 15.2% of samples were positive to Borrelia spp. Seropositivity was significantly higher in samples sent by PHCC doctors than those sent by Hospital doctors. Seropositivity was significantly higher in rural than in urban populations and in those who live in mountainous or flat areas. The percentage of seropositivity has increased over the years. Conclusions: The role of the PHCC doctor is essential for achieving an early diagnosis of Lyme disease, as a higher percentage of seropositives was detected in samples submitted from PHCC. Furthermore, most early localised LD patients were diagnosed in PHCC, avoiding the appearance of sequelae. Therefore, detection of Borrelia specific antibodies using an ELISA assay is a useful screening test for patients at risk of LD. © 2017 Elsevier España, S.L.U.


Vazquez-Lopez M.E.,Hospital Universitario Lucus Agusti | Diez-Morrondo C.,Hospital del Bierzo | Sanchez-Andrade A.,Hospital Universitario Lucus Agusti | Pego-Reigosa R.,Hospital Universitario Lucus Agusti | And 2 more authors.
Reumatologia Clinica | Year: 2016

Objectives: To determine the percentage of Lyme patients with articular manifestations in NW Spain and to know their evolution and response to treatment. Patients: A retrospective study (2006-2013) was performed using medical histories of confirmed cases of Lyme disease showing articular manifestations. Clinical and laboratory characteristics, together with the treatment and evolution of the patients, were analysed. Results: Seventeen out of 108 LD confirmed patients (15.7%) showed articular manifestations. Regarding those 17 patients, 64.7%, 29.4% and 5.9% presented arthritis, arthralgia and bursitis, respectively. The knee was the most affected joint. Articular manifestations were often associated to neurological, dermatological and cardiac pathologies. Otherwise, most patients were in Stage III. The 11.8% of the cases progressed to a recurrent chronic arthritis despite the administration of an appropriate treatment. Conclusions: Lyme disease patients showing articular manifestations should be included in the diagnosis of articular affections in areas of high risk of hard tick bite, in order to establish a suitable and early treatment and to avoid sequels. © 2015 Elsevier España, S.L.U. y Sociedad Española de Reumatología y Colegio Mexicano de Reumatología.


PubMed | Hospital Clinico Universitario, Hospital del Bierzo, University of Santiago de Compostela and Hospital Universitario Lucus Agusti
Type: | Journal: Reumatologia clinica | Year: 2015

To determine the percentage of Lyme patients with articular manifestations in NW Spain and to know their evolution and response to treatment.A retrospective study (2006-2013) was performed using medical histories of confirmed cases of Lyme disease showing articular manifestations. Clinical and laboratory characteristics, together with the treatment and evolution of the patients, were analysed.Seventeen out of 108 LD confirmed patients (15.7%) showed articular manifestations. Regarding those 17 patients, 64.7%, 29.4% and 5.9% presented arthritis, arthralgia and bursitis, respectively. The knee was the most affected joint. Articular manifestations were often associated to neurological, dermatological and cardiac pathologies. Otherwise, most patients were in Stage III. The 11.8% of the cases progressed to a recurrent chronic arthritis despite the administration of an appropriate treatment.Lyme disease patients showing articular manifestations should be included in the diagnosis of articular affections in areas of high risk of hard tick bite, in order to establish a suitable and early treatment and to avoid sequels.

Loading Hospital Universitario Lucus Agusti collaborators
Loading Hospital Universitario Lucus Agusti collaborators